Focusing on anti-BCMA CAR-T cells in multiple myeloma patients from the pivotal KarMMa-2 and -3 trials, we investigated the interactions that influence CAR-T cell function and treatment resistance. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.